Compumedics Limited revised earnings guidance for the fiscal year 2020. Full-year guidance lowered due to the impact that Coronavirus is likely to have on the Company's China-based business in second half of fiscal 2020. The company now expects sales of $40 million - $42 million (from $42 million - $44 million) and NPAT $4.0 million - $5.0 million (remains as originally guided).